Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
hUC-MSC for Hepatic Cirrhosis
NCT02652351Phase 1Unknown
- Sponsor
- Shenzhen Hornetcorn Biotechnology Co., Ltd.
- Start
- Mar 2016
- Primary completion
- May 2016
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of human umbilical cord mesenchymal stem cells in Liver cirrhosis (LC), sponsored by Shenzhen Hornetcorn Biotechnology Co., Ltd. Primary endpoint: Severity of adverse events at 12 months. Status: unknown.
02
Drugs
human umbilical cord mesenchymal stem cells
03
Conditions
Liver cirrhosis (LC)
Beyond the preview
Go deeper on NCT02652351.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02652351.